Method of treating chronic heart failure and pharmaceutical composition for complex therapy of chronic heart failure

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group relates to medicine, namely to cardiology, and deals with treatment of chronic heart failure. For this purpose pharmaceutical composition, containing activated potentiated forms of antibodies to angiotensin II receptor and to endothelial NO-synthase is introduced.

EFFECT: synergic action of pharmacological composition components ensures improvement of systolic function of left ventricle and increase of tolerance to physical load in said group of patients.

11 cl, 2 ex, 2 tbl

 

The invention relates to medicine and can be used to improve the effectiveness of adjuvant therapy in chronic heart failure, mainly in stage 1 and 2.

The prior art known drug for the treatment of chronic heart failure (CHF) on the basis of the activated - potentiated forms of ultra-low doses of antibodies to C-terminal fragment AT1-receptor of angiotensin II (a Comparative study of the cardioprotective actions of cardos valleys and losartan in experimental chronic heart failure. Tyurenkov I.N. and other Materials of the 9th all-Russian scientific and educational forum "Cardiology 2007". - Moscow, 2007, s-285). However this drug is not in all cases can provide sufficient therapeutic efficacy.

The invention is aimed at improving the efficiency of complex treatment of chronic heart failure, mainly in stage 1 and 2.

The solution of this problem is provided by the fact that in the treatment of chronic heart failure, by introducing into the body of a medicinal product on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to the receptor of angiotensin II, prepared by multiple consecutive breeding and external influences, according to the SNO invention additionally and simultaneously sachetana injected activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

Using the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase.

In addition, the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution of each component, obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

And use prepared in the form of a single drug - single dosage form a mixture of homeopathic dilutions of antibodies to C-terminal fragment AT1-receptor of angiotensin II in combination with a mixture of homeopathic dilutions of antibodies to endothelial NO-synthase.

This use of the pharmaceutical composition on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to C-terminal fragment AT1-Rotz is the Torah of angiotensin II and to endothelial NO-synthase in combination with known standard drugs used to treat diseases of the cardiovascular system of the following groups: ACE inhibitors, including combined, diuretics, β-blockers, nitrates, cardiac glycosides, calcium antagonists, lipid-lowering means, antiplatelet agents, antihypoxants, anticoagulants.

The solution of this problem is provided by the fact that drug for the treatment of chronic heart failure on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to the angiotensin II receptor according to the invention is made in the form of a pharmaceutical composition and further comprises as a reinforcing component of the activated - potentiated form of antibodies to endothelial NO-synthase.

When this activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution obtained in the process of consecutive multiple-dilution matrix solution of the corresponding antibodies in aqueous or aqueous-alcoholic solvent and an intermediate external mechanical impact - vertical shaking.

In addition, the pharmaceutical composition can be made in solid dosage form and contain the EF is objective number neutral media, saturated with a mixture of activated - potentiated form of antibodies to receptor of angiotensin II and an activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives, which may include lactose, cellulose microcrystalline and magnesium stearate.

When this aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to the receptor of angiotensin II and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

In addition, each of the components of ultra-low doses of affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilutions.

In addition, the pharmaceutical composition contains : active ingredients: activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase in the ratio of 1:1, with each component used in ultra-low dose in the form of a mixture of three corresponding matrix solutions, diluted in 10012, 10030and 100200once that is equivalent to boast of homeopathic dilutions With 12, 30,200.

Perhaps the claimed pharmaceutical composition based on the activated - potentiated form of ultra-low doses of affinity purified antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase also be used in combination with known standard drugs used for the treatment of diseases of the cardiovascular system of the following groups:

- ACE inhibitors, including combined (Enap, enalapril, capoten, Renitec, Prestarium (berlipril, Diroton, capoten, quadrupel, monopril, Renitec, Prestarium, noliprel-Forte, Enap-N));

- diuretics (furosemide, verospiron, gipotiazid, arifona retard, diver, indap, indapamide);

- β-blockers (egilok, atenolol, Concor, betaloc ZOK);

- nitrates (dilucida, kardiket, kardiket-record, metrolina, Monomac, monocycle, nitroglycerin, nitrosorbid, Ricard, petrol, sinopharm);

- cardiac glycosides (digoxin);

- calcium antagonists (normodipina, cordaflex, amlodipine, allows, Amlotop, cardilopin, cordipin PI);

- lipid-lowering means (vasilip, Liprimar, liponorm, simwagexal, simvasta, simvacard, simgal, Tulip);

- antiplatelet agents (aspirin, cardiac, cardiomagnyl, trombas);

- antihypoxants (Preductal MB, Preductal, trimetal);

- anticoagulants (warfarin).

Declared Pharma is eticheskuyu composition, it is recommended to take preferably, 1-2 tablets 2-4 times a day.

In the treatment of chronic heart failure may separate application in the form of two separately prepared drugs in the form of solutions and in solid dosage forms (tablets), each of which contains activated - potentiated form of ultra-low doses of affinity purified antibodies to C-terminal fragment AT1-receptor of angiotensin II and, accordingly, the activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

The proposed combination of activated - potentiated forms of antibodies to C-terminal fragment AT1-receptor of angiotensin II and endothelial synthase nitric oxide (NO-synthase) in the pharmaceutical composition (i.e. forms antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase, prepared by multiple consecutive breeding and intermediate external effects - vertical shaking, which has activity in pharmacological models and/or clinical treatment methods CHF) provides an unexpected synergistic therapeutic effect that is more pronounced effect on vascular remodeling and endothelial dysfunction, which plays a significant role in the development and progressioni the HSN, as well as improving the quality of life of patients, morphological and functional parameters of the heart and the tolerance to physical activity, which is confirmed by clinical tests.

In this application of the claimed pharmaceutical compositions for the treatment of patients with diseases of the cardiovascular system leads to improved quality of life, particularly in patients improve the quality of life, assessed according to the criteria of depression, anxiety, duration of the walk, the greater tolerance to physical activity, etc.

In addition, obtained in accordance with the invention, the technical solution expands the Arsenal of drugs for the treatment of chronic heart failure.

The pharmaceutical composition is prepared mainly as follows.

To prepare gomeopatichesky activated - potentiated form of active components, using monoclonal or, mostly, polyclonal antibodies, which can be obtained by known technologies-techniques are described, for example, in the book of Immunological methods, Ed. by Grimes. - M.: Medicine, 1987, p.9-33; or, for example, article Laffly, E., R. Sodoyer Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after. - 2005 - Vol.14. - N 1-2. P.33-55.

Monoclonal antibodies receive, for example, using hybridoma those who sociology. Moreover, the initial stage of the process includes immunization, based on the principles already developed in the preparation of polyclonal antisera. Further stages include obtaining hybrid cells that produce clones of the same specificity of antibodies. Their separation into individual form is carried out in the same manner as in the case of polyclonal antisera.

Polyclonal antibodies can be obtained by active immunization of animals. For this purpose a specially designed circuit animals make a series of injections required in accordance with the invention substance - antigen: endothelial NO-synthase and C-end fragment AT1receptors of angiotensin II. As a result of this procedure is to get the monospecific anticigarette with a high content of antibodies, which is used to produce an activated - potentiated form. If necessary, conduct the purification of antibody present in anticigarette, for example, by the method of affinity chromatography, by application of salt fractionation by precipitation or ion exchange chromatography.

Preferred for the preparation of the claimed pharmaceutical compositions is the use of polyclonal antibodies to endothelial NO-synthase and C-terminal fragment AT1the angiotensin receptor is II, which as a matrix (primary) solution with a concentration of 0.5-5.0 mg/ml is used for the subsequent preparation of the activated - potentiated form.

Preferred for the preparation of each component is the use of a mixture of three aqueous-alcohol dilutions of the initial matrix solution of antibodies, diluted, respectively, in the 10012, 10030and 100200time, which corresponds to boast of homeopathic dilutions With 12, 30 and 200. In carrying out the stated drugs in solid dosage form on the lactose is applied a mixture of these components.

Preferred for the preparation of the claimed medicinal preparation is the use of polyclonal antibodies to C-terminal fragment AT1-receptor of angiotensin II and endothelial NO-synthase, which can be obtained by immunization of rabbits as follows.

To obtain polyclonal antibodies to C-terminal fragment AT1-angiotensin II receptor as an immunogen (antigen) for immunization of rabbits using adjuvant and C-terminal fragment AT1-angiotensin II receptor selected, for example, from the following groups:

GKKFK RYFLQLLKYI PPKAKSHSNL STKMSTLSYR PSDNVSSSTK KPAPCFEVE

LNPF FYVFFGKNFK KYFLQLIKYI PPNVSTHPSL TTKMSSLSYR

PPENIRLPTK

KTAGSFDTE

QLLKYI PPKA

SSLSYR PPENIR

QLIKYI PPNVSTHP

SNL STKMSTLSYR PSDNVSSSTK KPACF

It is possible to obtain polyclonal antibodies to C-terminal fragment AT1-receptor of angiotensin II using as immunogen (antigen) C-terminal fragment of the receptor AT1-angiotensin II person added to the N end of the Cysteine (S):

CGKKF KRYFL QLLKY IPPKA KSHSN LSTKM STLSY RPSDN VSSST CCRR CFEVE

Before taking the blood sample for 7-9 days spend 1-3 intravenous injection for raising antibodies. In the process of immunization in rabbits take small blood samples to estimate the number of antibodies. The maximum level of immune response to the introduction of most soluble antigens is achieved in 40-60 days after the first injection. After completion of the first cycle immunization of rabbits for 30 days to give to restore health and are reimmunization including 1-3 intravenous injection. To obtain antisera from immunized rabbits collect the blood in a centrifuge tube with a volume of 50 ml using a wooden spatula to remove from the walls of the tube formed clots and put the wand in the clot formed in the center of the tube. The blood is placed in a refrigerator (4°C) overnight. The next day remove the clot adhered to the spatula, and centrifuged remaining liquid at 13,000 g for 10 min. the Supernatant (supernatant) is anticorodal. Received Antis is the crank should be yellow. Add to anticigarette 20% (weight concentration) NaN3to a final concentration of 0.02% and stored until use in a frozen state at -20°C. For allocation from the antisera antibody to C-terminal fragment AT1-angiotensin II receptor produce absorption in the solid phase in the following sequence:

1. 10 ml of rabbit antisera diluted 2 times with 0.15 M NaCl, type of 6.26 g of Na2SO4, mixed and incubated for 12-16 h at 4°C;

2. the precipitation is removed by centrifugation, dissolved in 10 ml of phosphate buffer and then cialiswhat against the same buffer overnight at room temperature;

3. after removal of the precipitate by centrifugation, the solution was applied to the column with DEAE-cellulose, equilibrated with phosphate buffer;

4. the fraction of antibodies determined by measuring the optical density of the eluate at 280 nm.

Then make a clearance antibodies by the method of affinity chromatography obtained by attaching antibodies to C-terminal fragment AT1receptors of angiotensin II, which is insoluble matrix followed by elution with concentrated salt solutions.

Received, therefore, a buffer solution of rabbit polyclonal antibody to C-terminal fragment AT1-angiotensin II receptor, purified on antigen, with a concentration of 0.5÷5,0 is g/ml, preferably of 2.5÷3.0 mg/ml, used as a matrix (primary) solution for the subsequent preparation of the activated - potentiated form.

Polyclonal antibodies to endothelial NO-synthase get similar to the above method, using as immunogen (antigen) for immunization of rabbits with adjuvant whole molecule endothelial NO-synthase following sequence:

1 MGNLKSVGQE PGPPCGLGLG LGLGLCGKQG PASPAPEPSR

ARARATYAN DHSPAPNSPT

61 LTRPPEGPKF PRVKNWELGS ITYDTLCAQS QQDGPCTPRR

CLGSLVLPRK LQTRPSPGPP

121 PAEQLLSQAR DFINQYYSSI KRSGSQAHEE RLQEVEAEVA

STGTIHLRES ELVFGAKQAW

181 RNAPRCVGRI QWGKLQVFDA RDCSSAQEMF TYICNHIKYA

TNRGNLRSAI TVFPQRAPGR

241 GDFRIWNSQL VRYAGYRQQD GSVRGDPANV EITELCIQHG

WTPGNGRFDV LPLLLQAPDE

301 APELFVLPPE LVLEVPLGAP HTGVVRGPGL RWYALPAVSN

MLLEIGGLEF SAAPFSGWYM

361 STEIGTRNLC DPHRYNILED VAVCMDLDTR TTSSLWKDKA

AVEINLAVLH SFQLAKVTIV

421 DHHAATVSFM KHLDNEQKAR GGCPADWAWI VPPIYGSLPP

VFHQEMVNYI LSPAFRYQPD

481 PWKGSATKGA GITRKKTFKE VANAVKISAS LMGTLMAKRV

KATILYASET GRAQSYAQQL

541 GRLFRKAFDP RVLCMDEYDV VSLEHEALVL VVTSTFGNGD

PPENGESFAA ALMEMSGPYN

601 SSPRPEQHKS YKIRFNSVSC SDPLVSSWRR KRKESSNTDS

AGALGTLRFC VFGLGSRAYP

661 HFCAFARAVD TRLEELGGER LLQLGQGDEL CGQEEAFRGW

AKAAFQASCE TFCVGEEAKA

721 AAQDIFSPKR SWKRQRYRLS AQAEGLQLLP GLIHVHRRKM

FQATVLSVEN LQSSKSTRAT

781 ILVRLDTAGQ EGLQYQPGDH IGISAPNRPG LVEALLSRVE

DPPPPTESVA VEQLEKGSPG

841 GPPPSWVRDP RLPPCTVRQA LTFFLDITSP PSPRLLRLLS

TLAEEPSEQQ ELETLSQDPR

901 RYEEWKLVRC PTLLEVLEQF PSVALPAPLL LTQLPLLQPR

YYSVSSAPNA HPGEVHLTVA

961 VLAYRTQDGL GPLHYGVCST WLSQLKTGDP VPCFIRGAPS

FRLPPDPYVP CILVGPGTGI

1021 APFRGFWQER LHDIESKGLQ PHPMTLVFGC RCSQLDHLYR

DEVQDAQERG VFGRVLTAFS

1081 REPDSPKTYV QDILRTELAA EVHRVLCLER GHMFVCGDVT

MATSVLQTVQRILATEGDME

1141 LDEAGDVIGV LRDQQRYHED IFGLTLRTQE VTSRIRTQSF

SLQERHLRGA VPWAFDPPGP

1201 DTPGP

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunogen (antigen) of whole molecules of endothelial NO-synthase following sequence:

1 MGNLKSVAQE PGPPCGLGLG LGLGLCGKQG PATPAPEPSR APASLLPPAP EHSPPSSPLT

61 QPPEGPKFPR VKNWEVGSIT YDTLSAQAQQ DGPCTPRRCL

GSLVFPRKLQ GRPSPGPPAP

121 EQLLSQARDF INQYYSSIKR SGSQAHEQRL QEVEAEVAAT

GTYQLRESEL VFGAKQAWRN

181 APRCVGRIQW GKLQVFDARD CRSAQEMFTY ICNHIKYATN

RGNLRSAITV FPQRCPGRGD

241 FRIWNSQLVR YAGYRQQDGS VRGDPANVEI TELCIQHGWT

PGNGRFDVLP LLLQAPDDPP

301 ELFLLPPELV LEVPLEHPTL EWFAALGLRW YALPAVSNML

LEIGGLEFPA APFSGWYMST

361 EIGTRNLCDP HRYNILEDVA VCMDLDTRTT SSLWKDKAAV

EINVAVLHSY QLAKVTIVDH

421 HAATASFMKH LENEQKARGG CPADWAWIVP PISGSLTPVF

HQEMVNYFLS PAFRYQPDPW

481 KGSAAKGTGI TRKKTFKEVA NAVKISASLM GTVMAKRVKA

TILYGSETGR AQSYAQQLGR

541 LFRKAFDPRV LCMDEYDVVS LEHETLWLVV TSTFGNGDPP

ENGESFAAAL MEMSGPYNSS

601 PRPEQHKSYK IRFNSISCSD PLVSSWRRKR KESSNTDSAG

ALGTLRFCVF GLGSRAYPHF

661 CAFARAVDTR LEELGGERLL QLGQGDELCG QEEAFRGWAQ

AAFQAACETF CVGEDAKAAA

721 RDIFSPKRSW KRQRYRLSAQ AEGLQLLPGL IHVHRRKMFQ

ATIRSVENLQ SSKSTRATIL

781 VRLDTGGQEG LQYQPGDHIG VCPPNRPGLV EALLSRVEDP

PAPTEPVAVE QLEKGSPGGP

841 PPGWVRDPRL PPCTLRQALT FFLDITSPPS PQLLRLLSTL

AEEPREQQEL EALSQDPRRY

901 EEWKWFRCPT LLEVLEQFPS VALPAPLLLT QLPLLQPRYY

SVSSAPSTHP GEIHLTVAVL

961 AYRTQDGLGP LHYGVCSTWL SQLKPGDPVP CFIRGAPSFR

LPPDPSLPCI LVGPGTGIAP

1021 FRGFWQERLH DIESKGLQPT PMTLVFGCRC SQLDHLYRDE

VQNAQQRGVF GRVLTAFSRE

1081 PDNPKTYVQD ILRTELAAEV HRVLCLERGH MFVCGDVTMA

TNVLQTVQRI LATEGDMELD

1141 EAGDVIGVLR DQQRYHEDIF GLTLRTQEVT SRIRTQSFSL

QERQLRGAVP WAFEPPGSDT

1201 NSP

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunodeficiency, is ogena (antigen) a synthetic peptide of endothelial NO-synthase, selected, for example, of the following amino acid sequences:

1192-1195

PWAF

1189-1192:

RGAVP

1185-1205

RHLRGAVPWAF DPPGPDTPGP

1194-1205:

AF DPPGPDTPGP

1186-1196:

HLRGAVPWAF D

1186-1205:

HLRGAVPWAF DPPGPDTPGP

The activated - potentiated form of each component is prepared by uniformly reducing the concentration in the serial dilutions 1 of the above matrix solution of 9 parts (for decimal dilution), or in 99 parts (for centesimal dilution), or in 999 parts (for the thousandth breeding) neutral solvent with multiple vertical shaking ("dynamics") of each received cultivation and use separate containers for each subsequent breeding until you get the desired potency - ratio cultivation in homeopathic method (see, for example, Usabe "Homeopathic medicinal product". - M., 1967, p.14-29).

For example, for the preparation of the 12th centesimal dilution With 12 one part of the mentioned matrix solution of antibodies to C-terminal fragment AT1-receptor of angiotensin II with a concentration of 3.0 mg/ml diluted in 99 parts of a neutral aqueous or aqueous-alcoholic solvent (mainly 15% ethanol) and repeatedly (10 times or more) vertically shaken - potentiate received 1st somenoe 1 razvedeniem the 1st centesimal 1 breeding prepare 2nd somenoe breeding 2. This operation is repeated 11 times, getting 12th somenoe breeding 12. Thus, 12th somenoe breeding With 12 represents the solution obtained by diluting consistently in different tanks 12 times the 1st part of the initial matrix solution of antibodies to C-terminal fragment AT1-receptor of angiotensin II with a concentration of 3.0 mg/ml in 99 parts of a neutral solvent, i.e. a solution prepared from a matrix solution and diluted to 10012once that is equivalent SITENAME homeopathic dilution With 12. Similar operations with a corresponding multiplicity of cultivation is performed to obtain a dilution With 30 and 200.

When used as a biologically active liquid component of the mixture of different homeopathic, mainly centesimal, dilution of the active substance each component of the composition (for example, 12, 30, 200) prepare separately for the above-described technology to their penultimate cultivation (respectively, to obtain 11, 29, 199) and then applied in accordance with the composition of the mixture in one container, one part of each component and mixed with the required amount of solvent (respectively, with 97 parts for centesimal dilution). You get the activated - potentiated form of antibodies to C-terminal fragment of al1-receptor of angiotensin II in the light of what maloi the dose of each component, made with a matrix solution and diluted to 10012in the 10030in the 100200that is equivalent to a mixture of centesimal homeopathic dilution With 12, 30 and 200.

You can use the active substance in the form of a mixture of different homeopathic dilutions, such as decimal or centesimal (D 20, 30, 100, or 12, 30, 50 etc), the effectiveness of which is determined experimentally.

When potentiation instead of shaking in the process of reducing the concentration can also be external effects of ultrasound, electromagnetic or other physical effects.

To obtain the claimed pharmaceutical compositions are aqueous or aqueous-alcoholic solutions of the active components are mixed, predominantly, in the ratio of 1:1 and used in liquid dosage form. Preferably the pharmaceutical composition comprises an activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase in ultra-low dose of each component prepared from a matrix solution and diluted to 10012in the 10030in the 100200that is equivalent to a mixture of centesimal homeopathic dilutions With 12, 30 and 200.

The claimed pharmaceutical composition can be used in solid dosage form, which sod is RIT effective amount of granules neutral media - lactose, saturated by soaking up the saturation a mixture of aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives, including, primarily, lactose, cellulose microcrystalline and magnesium stearate.

For solid oral forms of the claimed medicinal product produced in the plant fluidized bed (for example, type "Huttlin Pilotlab" production company Huttlin GmbH) irrigation until saturation of injected fluid - fluidized bed granules of neutral matter - of lactose (milk sugar) with a particle size of 150÷300 μm pre-obtained aqueous or aqueous-alcoholic solution of activated - potentiated forms of antibodies to C-terminal fragment AT1-receptor of angiotensin II and endothelial synthase nitric oxide (NO-synthase), mainly in the ratio of 1 kg of the solution of antibodies to 5 or 10 kg of lactose (1:5-1:10) with simultaneous drying in a stream supplied under the grate of heated air at a temperature not exceeding 40°C. the Estimated number 0,17-0,34 by weight of the solid oral form of dried granules, saturated activated - potentiated form of antibodies, are loaded into the mixer and the Pach is up with microcrystalline cellulose, enter in the number of 3-8 wt. parts by weight of the total load from the mass of solid oral forms. Then to this mixture 25-45 wt. parts by weight of the total load "unsaturated" pure lactose (to reduce the cost and some simplification and acceleration of the process without reducing the effectiveness of therapeutic effects) and magnesium stearate in an amount of 0.1-0.3 mass. parts by weight of the total load. The obtained tablets weight evenly mixed and tabletirujut direct dry pressing (for example, in tablet press Korsch XL 400) with the formation of round tablets weight 150-500 mg After tabletting get a tablet weight of 300 mg, impregnated with a water-alcohol solution (3,0-6,0 mg/tab.) the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and NO-synthase in ultra-low dose of each component prepared from a matrix solution and diluted to 10012in the 10030in the 100200that is equivalent to a mixture of centesimal homeopathic dilutions With 12, 30 and 200.

Preferably the claimed pharmaceutical composition is recommended to take 1-2 tablets 2-4 times a day.

For the experimental studies were used antibodies, cooked to order specialized pharmaceutical company.

Example 1.

For the experiment is analnogo research on the effectiveness of the claimed technical solution was used pharmaceutical composition, containing aqueous solutions of activated - potentiated forms of ultra-low-dose - MD) antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase, matrix prepared from (source) solution with a concentration of 3.0 mg/ml, with each component taken in a mixture of homeopathic dilutions With 12, 30, 200. The study was conducted on 80 patients in a double-blind, placebo-controlled, randomized study. Patients (CHF II-IV functional class (FC), and ejection fraction of the left ventricle (LVEF) less than 40%) were divided into 4 equal groups: within 6 months in addition to primary therapy (β-blocker bisoprolol, the ACE inhibitor enalapril, in the absence of contraindications aspirin, allowed diuretics, nitrates, digoxin) group 1 received SMD antibodies to C-terminal fragment AT1-angiotensin II receptor (a mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 2 - SMD antibodies to endothelial NO-synthase (mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 3 pharmaceutical composition on the basis of ULD of antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase (mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 4 - placebo (3 tablets/day, n=20). The groups were matched by source the m characteristics: by sex and age and severity (FC CHF and LVEF) and duration of disease.

Before and after treatment in patients assessed the effect of administered drugs on vascular remodeling and endothelial dysfunction, which plays a significant role in the development and progression of chronic heart failure.

The effect of drugs on the processes of vascular remodeling was assessed by the velocity of propagation of pulse wave (SST) system ("Colson") on carotid-femoral (CF) (elastic type) and carotid-radial (CR) (muscle type) segments of arteries.

Table 1 shows the dynamics of the propagation velocity of the pulse wave at the carotid-femoral (CF) (elastic type) and carotid-radial (CR) (muscle type) segments of arteries.

After 6 months of treatment only in group 3 there was a significant effect of the claimed pharmaceutical compositions on the stiffness of the arteries of the muscular type. In group 1, the receiving of ULD of antibodies to C-terminal fragment AT1receptors of angiotensin II, and in group 3, receiving the claimed pharmaceutical composition, was significantly increased stiffness of the elastic type arteries.

Example 2.

For experimental research on the effectiveness of the claimed technical solution was used pharmaceutical composition comprising aqueous solutions of activated - potentiated forms of ultra-low-dose - MD) antibodies to C-terminal fragment AT1-receptor angio who ensina II and to endothelial NO-synthase, made from the matrix (the original) solution with a concentration of 3.0 mg/ml, with each component taken in a mixture of homeopathic dilutions With 12, 30, 200. The study was conducted on 80 patients in a double-blind, placebo-controlled, randomized study. Patients (CHF II-IV functional class (FC), and ejection fraction of the left ventricle (LVEF) less than 40%) were divided into 4 equal groups: within 6 months in addition to primary therapy (β-blocker bisoprolol, the ACE inhibitor enalapril, in the absence of contraindications aspirin, allowed diuretics, nitrates, digoxin) group 1 received SMD antibodies to C-terminal fragment AT1-angiotensin II receptor (a mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 2 - SMD antibodies to endothelial NO-synthase (mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 3 - the claimed pharmaceutical composition on the basis of ULD of antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase (mixture of homeopathic dilutions With 12, 30, 200) (3 tabs/day, n=20); group 4 - placebo (3 tablets/day, n=20). The groups were comparable on baseline characteristics: by sex and age and severity (FC CHF and LVEF) and duration of disease.

Before and after treatment of the patients were evaluated quality of life (Minnesota and Kansas the cue questionnaires), morphological and functional parameters of the heart and tolerance to physical load.

The results of the study in the dynamics of the main indicators of the effectiveness of treatment are shown in table 2.

After 6 months of treatment in group 1 patients treated SMD antibodies to C-terminal fragment AT1receptors of angiotensin II, it was noted the significant improvement of quality of life, improvement of systolic function of the left ventricle, increased tolerance to physical activity. In group 2 was significantly decreased levels of anxiety and depression and quality of life, assessed using the Kansas questionnaire. The study showed that the greatest therapeutic effect when added to standard therapy of chronic heart failure has claimed pharmaceutical composition, which was given to group 3, which was recorded significant positive trend for all the studied parameters.

The proposed combination of activated - potentiated forms of antibodies to C-terminal fragment AT1-receptor of angiotensin II and endothelial synthase nitric oxide (NO-synthase) in the pharmaceutical composition provides an unexpected synergistic therapeutic effect that is more pronounced effect on vascular remodeling and endothelial dysfunction, which plays snackwell in the development and progression of CHF, as well as improving the quality of life of patients, morphological and functional parameters of the heart and the tolerance to physical activity, which is confirmed by clinical tests.

1. The method of treatment of chronic heart failure, by introducing into the body of a medicinal product on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to the receptor of angiotensin II, prepared by multiple consecutive breeding and external influences, characterized in that additionally at the same time and sachetana enter the activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

2. The method according to claim 1, characterized in that use activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase.

3. The method according to claim 1 or 2, characterized in that the activated - potentiated form of antibodies to C-terminal fragment AT1-receptor of angiotensin II and the activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or water-alcohol rest the RA of each component, obtained during consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

4. The method of treatment according to claim 1 or 2, characterized in that use is prepared in the form of a single drug - single dosage form a mixture of homeopathic dilutions of antibodies to C-terminal fragment AT1-receptor of angiotensin II in combination with a mixture of homeopathic dilutions of antibodies to endothelial NO-synthase.

5. The method of treatment according to claim 1 or 2, characterized by the fact that the use of the pharmaceutical composition on the basis of the activated - potentiated form of ultra-low doses of affinity purified antibodies to C-terminal fragment AT1-receptor of angiotensin II and to endothelial NO-synthase in combination with known standard drugs used for the treatment of diseases of the cardiovascular system, the following groups: ACE inhibitors, including combined, diuretics, β-blockers, nitrates, cardiac glycosides, calcium antagonists, lipid-lowering means, antiplatelet agents, antihypoxants, anticoagulants.

6. Drug for the treatment of chronic heart failure on the basis of the activated - potentsiala the Noi form of ultra-low doses of affinity purified antibodies to the receptor of angiotensin II, characterized by the fact that made in the form of a pharmaceutical composition and further comprises as a reinforcing component of the activated - potentiated form of antibodies to endothelial NO-synthase.

7. The drug according to claim 6, characterized in that the activated - potentiated form of antibodies to receptor of angiotensin II and to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution obtained in the process of consecutive multiple-dilution matrix solution of the corresponding antibodies in aqueous or aqueous-alcoholic solvent and an intermediate external mechanical impact - vertical shaking.

8. The drug according to claim 6 or 7, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of a neutral carrier, saturated with a mixture of activated - potentiated form of antibodies to receptor of angiotensin II and an activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives.

9. The drug according to claim 6 or 7, characterized in that an aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to receptor of angiotensin II and indot lialei NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to the receptor of angiotensin II and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

10. The drug according to claim 6 or 7, characterized in that each of the components of ultra-low doses of affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilutions.

11. The drug of claim 8, characterized in that the pharmaceutically acceptable additives include lactose, cellulose microcrystalline and magnesium stearate.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine and deals with an application of an antibody, which binds with residues of 1-5 or 3-7 A-beta, to reduce vascular amyloid in a patient with cerebral amyloid angiopathy, with the antibody being introduced intravenously or subcutaneously.

EFFECT: invention provides purification of the patient's vessels from amyloid deposits.

9 cl, 2 ex, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy, and concerns treating vegetovascular dystonia (VVD). That is ensured by administering a pharmaceutical composition containing activated potentiated angiotensin II receptor antibodies and activated potentiated endothelial NO-synthase antibodies.

EFFECT: method provides effective treatment of vegetovascular dystonia ensured by the synergetic action of the ingredients of the pharmaceutical composition.

1 ex, 1 tbl

FIELD: biotechnology.

SUBSTANCE: invention relates to binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC-EEG) of the formula [(EEGS)2Fe2(NO)4] with the structural formula: , where R-S represents ethyl ether of glutathione containing a thiol group. The invention also relates to a composition for reducing functional disorders of myocardium subjected to hypoxia-reoxygenation which contains binuclear form of dinitrosyl iron complex with ethyl ether of glutathione (DNIC EEG) as defined above and a pharmaceutically acceptable carrier. Also the use of DNIC-EEG is disclosed as antihypoxic agent.

EFFECT: reduction of hypoxic contracture, arrhythmias intensity and improvement of recovery of contractile function of the heart after reoxygenation.

3 cl, 1 tbl, 16 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.

EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.

22 cl, 27 dwg, 1 tbl, 756 ex

FIELD: medicine.

SUBSTANCE: method involves preliminary intraperitoneal single administration of 5% aqueous alloxan in a dose of 15 mg/kg of body weight into a rat's body on an empty stomach. That is followed by administering afobazol under conditions of oxidative stress after observing the rat's blood glucose gain at least twice. Afobazol is administered subcutaneously in a dose of 10 mg/kg of body weight once a day for 30 days with underlying administration of L-arginine in a dose of 10 mg/kg of body weight or with underlying NG-nitroarginine methyl ester (L-NAME)-inhibitor of NOS-3 enzyme in a dose of 25 mg/kg of animal's weight.

EFFECT: method enables correcting the oxidative stress and NO-producing endothelial dysfunction accompanying vascular complications of diabetes mellitus.

1 dwg, 6 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: kit of apiphytoagents containing: 'Bee active Tentorium' pills, 'Khlebina' pills, 'Apiphytotonus' apicomposition, 'Assile-concentrate' aqueous solution, 'Apihit' oily solution, 'APV' aqueous solution, 'Tentorium Cream' cream for external application, for non-medicinal prevention of a cardiovascular risk and increase of the capacity in junior and young sportsmen. A method for non-medicinal prevention of the cardiovascular risk and increase of the capacity in junior and young sportsmen consisting in administering apiphytoproducts in certain regimens.

EFFECT: kit is effective for non-medicinal prevention of the cardiovascular risk and increase of the capacity in junior and young sportsmen.

2 cl, 16 dwg, 9 tbl

FIELD: medicine.

SUBSTANCE: complex of biologically active substances for treating and preventing cardiovascular diseases, recovered from sea urchin gonads Strongylocentrotus droebachiensis free from ballast substances, prepared by extraction of the purified gonads in 95% ethanol under certain conditions, separation of a dry ethanolic extract and drying. An agent for treating and preventing cardiovascular diseases containing the complex of biologically active substances.

EFFECT: complex and agent are effective in treating and preventing cardiovascular diseases.

4 cl, 1 dwg, 4 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and deals with a composition for treating cardiac tissue, containing TGFβ-1, BMP4, α-thrombin, cardiotrophin and cardiogenol C, a method of obtaining differentiated cells-cardioprecursors from mammalian stem cells, including cultivation of initial cells in presence of the said composition; a method of providing cardiac tissue with cardiomyocytes, which includes introduction of differentiated cells, obtained by the method of obtaining described above, into cardiac tissue.

EFFECT: group of inventions ensures an improved specificity in a regulation of transcription of genes, required for differentiation induction.

27 cl, 23 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns methods of treating growth hormone or insulin-like growth factor 1 deficiency in a patient involving administering an immunogenic amount of a vaccine containing a chimeric somatostatin-14 based polypeptide bound to inactivated chloramphenicol acetyltransferase (CAT), and an adjuvant; the vaccine for treating the patient having growth hormone or insulin-like growth factor 1 deficiency; a method of treating obesity in the patient involving administering the immunogenic amount of the vaccine.

EFFECT: group of inventions provide the immunogenicity for somatostatin and higher release of endogenously produced growth hormone and/or insulin-like growth factor 1.

22 cl, 8 ex, 6 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2.2.2]oct-5-en-2-yl isobutyric acid ester. Also, the invention refers to a pharmaceutical composition of the above crystalline salt and using the above crystalline salt for preparing the pharmaceutical composition.

EFFECT: what is prepared is the crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2,2,2]oct-5-en-2-yl isobutyric acid ester that can be effective as a L/T-type calcium channel blocker.

15 cl, 11 dwg, 10 tbl, 6 ex

Antibody to epha2 // 2525133

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of immunology, medicine and biotechnology. Claimed are versions of anti-EPHA2 antibodies. Claimed antibodies are bound with polypeptide, consisting of amino acids 426-534 in SEQ ID NO:8. Also described are hybridomes, which produce such antibodies, and pharmaceutical compositions and methods of application of said antibodies and compositions.

EFFECT: invention can be used in medicine.

74 cl, 14 dwg, 14 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the field of immunology. Disclosed is a method of treating rheumatoid arthritis, chronic arthritis in children or Castelman's disease, application of an antibody in the said method, as well as application of an antibody in production of a medication for treatment of rheumatoid arthritis, chronic arthritis in children or Castelman's disease. The antibody by the claimed invention possesses an improved antigen-neutralising ability, pharmacokinetics, immunogenicity, safety and physicochemical properties and can be further applied in therapy of diseases, associated with the activation of the receptor IL-6.

EFFECT: claimed is the medication for treatment of rheumatoid arthritis, chronic arthritis in children or Castelman's disease, representing the antibody against the receptor IL-6, obtained on the basis of the antibody TOCILIZUMAB.

12 cl, 5 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of biotechnology and immunology. Described are versions of antibodies, binding the GRM molecule, as well as their antigen-binding fragments, amino acid sequences of variable parts of which are presented in the claim materials. Nucleic acid, coding the said antibodies, is presented. Claimed is a method of obtaining the RGM-binding protein, which includes cultivation of a host cell in a culture medium under conditions suitable for obtaining the binding protein, capable of binding with RGM, where the host cell contains an expression vector, containing the separated nucleic acid, coding the said antibody. Described is a pharmaceutical composition for treating a disease, in which the SGM A activity produces a negative impact, which contains a therapeutically efficient quantity of the said antibody and a pharmaceutically acceptable carrier. Claimed is an application of the said antibody for obtaining a medication, used for a) reduction of hRGM A binding with a patient's Neogenin receptor; or b) for reduction of hRGM A binding with BMP-2 and BMP-4 in the patient.

EFFECT: invention makes it possible to obtain antibodies against GRM, which are used for treating diseases, associated with excessive interaction of RGM with the Neogenin receptor, BMP-2 and BMP-4.

13 cl, 16 dwg, 10 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to biotechnology and represents a polypeptide construction for treatment, prevention and relief of disorders, associated with an adhesion of platelets and platelet-mediated aggregation or its dysfunction, which includes one or more single-domain antibodies, aimed against the von Willebrand factor (vWF), and one or more single-domain antibodies aimed against serum albumen (SA). The invention also relates to nucleic acid, coding such polypeptide construction, to compositions, containing the said construction, and to its application for obtaining medications for prevention, treatment and relief of the said disorders.

EFFECT: claimed invention makes it possible to extend an assortment of medications for treatment, prevention and relief of disorders, associated with the platelet adhesion and platelet-associated aggregation or its dysfunction.

15 cl, 30 dwg, 32 tbl, 69 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and deals with a pharmaceutical composition for enhancing the efficiency of treatment of liver cancer by Sorafenib, with the said composition containing an anti-glypican 3-antibody as an active ingredient.

EFFECT: invention provides an improved anti-cancer effect and reduction of the side effect, in particular loss of the body weight.

14 cl, 9 dwg, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology and endocrinology, and concerns treating patients suffering from dyspepsia syndrome in a combination with overweight. That is ensured by therapy with preparations improving metabolism, promoting weight loss and fat absorption, as well as antidepressants. The therapy is differentiated taking into account an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, nutritional status assessed by bioimpedancemetry, a degree of manifestation of sleep disorders, eating behaviour typing, eating regimen and daily rhythm determination , level evaluation of glucose, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood, blood glucose tolerance, gustation, life quality assessment.

EFFECT: differentiated approach provides an effective treatment of dyspepsia in a combination with weight loss, correction of eating behaviour and metabolic processes.

2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy, and concerns treating vegetovascular dystonia (VVD). That is ensured by administering a pharmaceutical composition containing activated potentiated angiotensin II receptor antibodies and activated potentiated endothelial NO-synthase antibodies.

EFFECT: method provides effective treatment of vegetovascular dystonia ensured by the synergetic action of the ingredients of the pharmaceutical composition.

1 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, specifically cardiology, and concerns treating chronic cardiac failure. That is ensured by administering a pharmaceutical composition containing an activated potentiated form of very-low-dose angiotensin II receptor antibodies and an activated potentiated form of very-low-dose endothelial NO-synthase antibodies.

EFFECT: method provides improving quality of life and higher tolerance to physical loads in the given group of patients.

11 cl, 2 ex, 2 tbl

FIELD: veterinary medicine.

SUBSTANCE: method comprises hyperimmunisation of bulls-producers with inactivated antigens C1. perfringens, comprising toxoids and somatic antigens of bacteria of serotypes A, C and D in the culture medium with the following ratio of components per 1 litre of antigen: toxoid and somatic antigen of strain No 28 (type A) in the culture medium with a concentration of 1012 · (9-10) m.c. in 1 cm3, cm3 - 300.0-350.0; toxoid and somatic antigen of strain No 392 (type C) in the culture medium at a concentration of 1012 · (9-10) m.c. in 1 cm3, cm3 - 300.0-350.0; toxoid and somatic antigen of strain No 213 (type D) in the culture medium at a concentration of 1012 · (9-10) m.c. in 1 cm3, cm3 - 300.0-350.0; formalin, cm3 - 4.0-5.0. The additional hyperimmunisation of bulls-producers is carried out with inactivated antigens of E.coli, comprising somatic and adhesive antigens K99, A20 in saline, TL-, TS-toxoids of E.coli in the culture medium in the following ratio of components per 1 litre of antigen: somatic and adhesive antigen of strain KV-1 (K99) in saline with a concentration of 1012 · (14-15) bln.c. in 1 cm3, cm3 - 300.0-350.0; somatic and adhesive antigen of strain PZ-3 (A20) in saline with a concentration of 1012 · (14-15) m.c. in 1 cm3, cm3 - 300.0-350.0; formalin, cm3 - 4.0-5.0; thermostable and thermolabile toxoids of E. coli strains KV-1 and PZ-3 in the culture medium (DPR) 1:8-1:16, l - to 1. Hyperimmunisation of bulls-producers is carried out four times by subcutaneous injection in the neck region on one side of the antigen dose C1. perfringens and in the neck region on the other side - E.coli antigen dose, according to the following scheme: on the first day - 8 cm3, after 14 days - 10 cm3, after 28 days - 15 cm3, and after 42 days - 20 cm3 from blood, then serum is separated and preserved.

EFFECT: invention with the further intake enables to obtain the hyperimmune serum, which provides treatment and prevention of mixed infection - anaerobic enterotoxaemia and colibacillosis diarrhoea of calves.

5 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology and medicine. What is presented is a method for preventing or treating an ocular condition related to high expression or activity of a complement factor D involving administering an antibody or its antigen-binding fragment into an individual. There are presented an anti-factor D 20D12 antibody and its antigen-binding fragment to be used to prepare a therapeutic agent, as well as containing the above antibody or its antigen-binding fragment, a kit for treating the ocular condition related to high activity or expression of factor D.

EFFECT: invention can find further application in therapy of the complement system related diseases.

14 cl, 6 dwg, 3 tbl

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

Up!